Mainz Biomed (MYNZ) versus Its Rivals Head-To-Head Review

Mainz Biomed (NASDAQ:MYNZ) is one of 1,004 public companies in the “Pharmaceutical preparations” industry, but how does it contrast to its competitors? We will compare Mainz Biomed to related businesses based on the strength of its analyst recommendations, earnings, valuation, risk, profitability, dividends and institutional ownership.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Mainz Biomed and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mainz Biomed	0	1	1	0	2.50
Mainz Biomed Competitors	6648	19169	45551	960	2.56

Mainz Biomed currently has a consensus target price of $6.00, indicating a potential upside of 971.43%. As a group, “Pharmaceutical preparations” companies have a potential upside of 77.27%. Given Mainz Biomed’s higher possible upside, equities analysts clearly believe Mainz Biomed is more favorable than its competitors.

Insider and Institutional Ownership

44.5% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 18.2% of Mainz Biomed shares are held by insiders. Comparatively, 13.9% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Volatility & Risk

Mainz Biomed has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500. Comparatively, Mainz Biomed’s competitors have a beta of 0.79, indicating that their average stock price is 21% less volatile than the S&P 500.

Profitability

This table compares Mainz Biomed and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mainz Biomed	-2,934.82%	-488.05%	-145.77%
Mainz Biomed Competitors	-2,993.12%	-287.67%	-33.63%

Earnings & Valuation

This table compares Mainz Biomed and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Mainz Biomed	$900,000.00	-$26.30 million	-0.34
Mainz Biomed Competitors	$1.68 billion	$153.64 million	-3.19

Mainz Biomed’s competitors have higher revenue and earnings than Mainz Biomed. Mainz Biomed is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Summary

Mainz Biomed competitors beat Mainz Biomed on 9 of the 13 factors compared.

About Mainz Biomed

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.